Related Experiment Videos
How I treat Waldenström macroglobulinemia
1Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. steven_treon@dfci.harvard.edu
Blood
|July 21, 2009
Summary
Waldenström macroglobulinemia (WM) is a rare B-cell cancer. Treatment decisions for WM depend on disease severity and patient factors, with various therapeutic options available.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Waldenström macroglobulinemia (WM) is a lymphoplasmacytic B-cell lymphoma characterized by IgM-secreting cells.
- Genetic factors contribute to WM, with a notable familial predisposition in 20% of cases.
- Disease presentation ranges from asymptomatic to symptomatic, necessitating careful monitoring and intervention.
Purpose of the Study:
- To outline the management strategies for Waldenström macroglobulinemia.
- To delineate criteria for initiating therapy in WM patients.
- To review current and emerging treatment options for WM.
Main Methods:
- Observation for asymptomatic patients.
- Therapeutic intervention for symptomatic or advanced disease.
- Review of treatment modalities including plasmapheresis, rituximab-based regimens, and salvage therapies.
Main Results:
- Therapy is indicated for patients with specific clinical or laboratory findings, including anemia, thrombocytopenia, hyperviscosity, or organ involvement.
- First-line treatment options include rituximab monotherapy or combination regimens.
- Salvage therapy options encompass re-treatment, alternative regimens, and newer agents like bendamustine and everolimus.
Conclusions:
- Treatment selection for WM should be individualized based on patient status and treatment objectives.
- Plasmapheresis is valuable for hyperviscosity symptoms and rituximab prophylaxis.
- Ongoing research and novel agents offer expanding therapeutic avenues for WM management.
